Neurol. praxi. 2018;19(5):338-342 | DOI: 10.36290/neu.2018.148

Multiple sclerosis: treatment safety

doc. MUDr. Martin Vališ, Ph.D., MUDr. Zbyšek Pavelek
Neurologická klinika LF UK a FN, Hradec Králové

Multiple sclerosis is a chronic inflammatory autoimmune disease which affect central nervous system. Treatment initiation ofearly multiple sclerosis may postpone the development of disease progression and clinical activity, including magnetic resonancefindings and disablement. The aims of this paper is to describe options for treating multiple sclerosis and risks.

Keywords: multiple sclerosis, treatment safety

Received: January 22, 2018; Accepted: March 1, 2018; Prepublished online: March 1, 2018; Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vališ M, Pavelek Z. Multiple sclerosis: treatment safety. Neurol. praxi. 2018;19(5):338-342. doi: 10.36290/neu.2018.148.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017; 12: 59-63. Go to original source... Go to PubMed...
    2. Buraga I, Popovici R. Multiple sclerosis and pregnancy: cur-rent considerations. Scientific World J 2014; 2014: 513160. Go to original source... Go to PubMed...
    3. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(6): 545-556. Go to original source... Go to PubMed...
    4. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856): 1819-1828. Go to original source... Go to PubMed...
    5. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-1839. Go to original source... Go to PubMed...
    6. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13: 247-256. Go to original source... Go to PubMed...
    7. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg S?rensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 416-426. Go to original source... Go to PubMed...
    8. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010; 68(3): 295-303. Go to original source... Go to PubMed...
    9. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017; 376(3): 221-234. Go to original source... Go to PubMed...
    10. Chan A, de Seze J, Comabella M. Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis. CNS Drugs. 2016; 30(1): 41-51. Go to original source... Go to PubMed...
    11. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401. Go to original source... Go to PubMed...
    12. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; oral cladribine for early MS (ORACLE MS) Study Group. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014; 13(3): 257-267. Go to original source... Go to PubMed...
    13. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13: 977-986. Go to original source... Go to PubMed...
    14. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017; 376(3): 209-220. Go to original source... Go to PubMed...
    15. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006; 66: 894-900. Go to original source... Go to PubMed...
    16. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365: 1293-1303. Go to original source... Go to PubMed...
    17. Outteryck O, Zéphir H, Salleron J, Ongagna JC, Etxeberria A, Collongues N, Lacour A, Fleury MC, Blanc F, Giroux M, de Seze J, Vermersch P. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler. 2014; 20(7): 822-829. Go to original source... Go to PubMed...
    18. Phillips JT, Erwin A, Agrella S, Kremenchutzky M, Kramer JF, Darkes MJ, Kendter J, Abourjaily H, Rana J, Fox RJ. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a delphi study. Neurol Ther. 2015; 4(2): 137-146. Go to original source... Go to PubMed...
    19. Sheikh SI, Nestorov I, Russell H, O'Gorman J, Huang R, Milne GL, Scannevin RH, Novas M, Dawson KT. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013; 35(10): 1582-1594. Go to original source... Go to PubMed...
    20. Tintoré M. Rationale for early intervention with immunomodulatory treatments. J Neurol 2008; 255(Suppl. 1): 37-43. Go to original source...
    21. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999; 53(8): 1622-1627. Go to original source... Go to PubMed...
    22. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 2001; 24(13): 979-990. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.